Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected Unit-2, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from September 23 to 27, 2024. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI).
The above information is a part of company’s filings submitted to BSE.
